You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A comprehensive next generation sequencing diagnostic tool for lung infection among hospitalized patients

    SBC: PEAK DIAGNOSTIC PARTNERS LLC            Topic: NIAID

    ABSTRACT A major driver of intensive care unit (ICU) hospital admissions is pneumonia. The immunocompromised patient group, which makes up 20% of ICU pneumonia admissions, is at increased risk for severe infection from common respiratory organisms as well as opportunistic pathogens that cannot be easily cultured or treated with standard empiric antibiotics. While standard practice for clinical ide ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Infrastructure automation for connectomic image analysis

    SBC: Zetta AI LLC            Topic: 101

    The BRAIN 2025 report states that a major goal of the US BRAIN Initiative is "Generate circuit diagrams," and identifies electron microscopy (EM) as "the gold standard for circuit mapping." So far EM is the only approach that has ever delivered a connectome, a map of all synaptic connections in a nervous system or brain. After the C. elegans connectome in the 1980s, the labor of manual image analy ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study

    SBC: OLIGOMERIX INC            Topic: NIA

    PROJECT SUMMARY: This R44 application is focused on preparations for a phase 1b clinical study to look for early clinical signs of efficacy/proof-of-concept by evaluating the response to treatment of relevant serum and CSF biomarkers in a double blinded study of patients with Alzheimer’s Disease. The proposed work is designed to support longer term dosing required to see an effect on biomarkers. ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. miRNA drug for tendinopathy

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: R

    Project SummaryTendinopathy is a tendon disorder that is highly prevalent in the aged population. It is characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy and an urgent need for effective treatments for tendinopathy. The technology to be developed is microRNA (miR)-221 ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid phage-amplified immunoassay for phenotypic UTI diagnosis and antimicrobial susceptibility testing

    SBC: COBIO DIAGNOSTICS INC.            Topic: 400

    Abstract/ Summary Urinary tract infections (UTIs) are among the most common infection type in the U.S resulting in an estimated 10.5 million UTI-related office visits, 2-3 million emergency department visits, and over 100,000 hospitalizations in the U.S. annually at a cost of at least $3.5 billion. Sixty percent of women will experience at least one acute UTI in their lifetime. 25-50% of women hav ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Long-acting Stable Glucagons for Treatment of Hyperinsulinism

    SBC: AMIDEBIO, LLC            Topic: NIDDK

    SUMMARY/ABSTRACT In severe persistent hyperinsulinism (HI), repeated hypoglycemic episodes can ultimately lead to permanent seizure disorders, learning disabilities, cerebral palsy, blindness and even death. Clinical studies have demonstrated the effectiveness of both short-term and long-term treatment with glucagon for severe forms of HI and continuous subcutaneous administration of glucagon has ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Fluorescent IRE sensor for synucleinopathy drug discovery

    SBC: LUCERNA INC            Topic: 105

    ABSTRACT The goal of this Phase II proposal is to advance synucleinopathy disease drug discovery by validating a high- throughput screening (HTS)-ready assay and establish a RNA structure sensor platform for RNA-targeted drug discovery. Dementia with Lewy bodies is the second most common form of degenerative dementia in the elderly population after Alzheimer’s disease; and it is characterized by ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Lowering the burden of medical translation by enabling international healthcare professionals as human editors of machine translations

    SBC: Transcendent International, LLC            Topic: NIMHD

    PROJECT SUMMARY Language access solutions in healthcare have focused almost exclusively on the provision of verbal medical interpretation, despite federal and state laws that mandate translation of written information for patients with limited English proficiency (LEP). In recent years, machine translation (MT) has made significant strides, but when it comes to mission-critical technical materials ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Multi-probe minimally invasive endomicroscope

    SBC: Modendo Inc            Topic: NINDS

    PROJECT SUMMARY This project seeks to develop a multi-probe ultrathin endomicroscope to enable high-resolution imaging and photo-stimulation at multiple sites within currently inaccessible regions of the brain. The instrument will be amenable to scientific studies in model animals and a stepping stone for future medical instrumentation targeted at diagnosis and disease treatment in humans. The com ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition

    SBC: SENEX BIOTECHNOLOGY, INC.            Topic: 102

    Dysregulation of the PI3K/AKT/mTOR pathway is one of the most common genetic alterations in cancer, found in more than one third of all solid tumors. Inhibitors of the key components of this pathway (mTOR, PI3K, AKT) have been developed; some of them have been approved for breast cancer and for certain other malignancies. However, the benefits of these inhibitors are limited by the development of ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government